In January 2020 Semmelweis University welcomed a lecture from the guest speaker from the Leiden University Medical Center (LUMC) – Dr. Károly Szuhai, who became the 30th Eurolife Distinguished Lecturer.
During the information workshop on Eurolife Network hosted by the Semmelweis University, Dr. Szuhai presented a lecture titled: Molecular genomic technology in tumor genetics, in which he presented an overview of the development of molecular test methods in cancer research over the past two decades. He explained that cancer is a genetic disease that occurs because certain genetic changes occur, and in order to be able to examine them with proper resolution, various research and diagnostic tools need to be developed.
For over 20 years in Leiden, he has devoted himself to the development and application of these techniques, and in his presentation he has introduced the most advanced techniques used today. His presentation was received with a great enthusiasm by the audience and Dr. Szuhai was awarded the Eurolife Medal in recognition of his achievements in the field of Life Sciences.
About Dr. Károly Szuhai
The research aim of Dr. Szuhai is to elucidate molecular genetic changes that are responsible for sarcoma development, progression or prognosis by using a wide range of molecular cytogenetic tools thereby improving genetic classification of these tumour entities allowing stratification for better diagnosis and treatment. This translational research activity connected basic science (genetics and modelling) with applied clinical research (diagnostics, clinical classification) for bone and soft tissue tumours.
Dr. Szuhai graduated as a medical doctor at Pecs University Medical School in Pecs, Hungary and worked as clinical fellow before started his PhD. In 2001 he obtained his PhD in Molecular Pathology at Leiden University to develop and translate molecular pathology techniques in cancer and mitochondrial diseases. As a post doc, he stayed at the Molecular Cell Biology department and started a joint project on molecular genetics of bone and soft tissue tumours with the Pathology department, LUMC. His background in medicine and passion in developing in applying molecular techniques to translational research was the basis to join and stay at the department of Molecular Cell Biology. Since 2013 he works as associate professor. He works in collaboration with the Pathology department with the group of Prof Bovee as his work has a strong translational focus where obtained results and their translation is needed using clinical material giving a strong synergy for the research. Furthermore, he is the coordinator of the half minor on Molecular Targets and Cancer Therapy.